AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02559336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated palliative oncology care
Description: Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
Study NCT00886340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard care
Description: One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
Study NCT00886340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Enhanced standard care Six appointments with nurse practitioner (20 minutes)
Study NCT05858697 — intervention group
Intervention type: OTHER
Intervention: Declining participation in the Aarhus intervention
Description: Each year a fraction of the children invited into the Aarhus intervention decline to participated.
Study NCT05858697 — intervention group
Intervention type: BEHAVIORAL
Intervention: Participation in the Aarhus intervention
Description: A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
Study NCT02939040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Activities
Description: The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery.
Study NCT02502812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F2
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study NCT03653455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email reminders
Description: Patients will receive email reminders until their PROs are completed.
Study NCT03653455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre- and Post-operative discussion
Description: Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
Study NCT01797471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
Description: A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
Study NCT02755480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultralow Dose Thoracic Computed Tomography
Description: Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
Study NCT04741035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sternal precautions
Description: Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position
Study NCT04741035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sternal precautions
Description: Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
Study NCT04096391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flowonix Prometra® II Programmable Infusion System
Description: The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
Study NCT04096391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Medicine
Description: Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
Study NCT03895099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel early follicular phase
Description: Start of ovarian stimulation in early follicular phase
Study NCT03653455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
Study NCT03455374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with CSI atherectomy device
Description: Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
Study NCT00833560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
Study NCT00833560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Study NCT00833560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Study NCT03895099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel medium follicular phase
Description: Start of ovarian stimulation in medium follicular phase
Study NCT02555540 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment
Study NCT03895099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel ovulatory phase
Description: Start of ovarian stimulation in ate follicular phase
Study NCT03895099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel late follicular phase
Description: Start of ovarian stimulation in ovulatory Phase
Study NCT03895099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel luteal phase
Description: Start of ovarian stimulation in luteal phase
Study NCT00682383 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Description: Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle
Study NCT00112489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00112489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02783391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG and intracortical electrodes
Study NCT02502812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study NCT02555540 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Randomised assignment
Study NCT02454465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy group
Description: Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
Study NCT03033862 — intervention group
Intervention type: DEVICE
Intervention: Bioresorbable Vascular Scaffold
Description: Bioresorbable Vascular Scaffold
Study NCT03033862 — intervention group
Intervention type: DEVICE
Intervention: Drug Eluting Stent
Description: Drug Eluting Stent
Study NCT02527434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab monotherapy
Description: IV infusion
Study NCT02527434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 monotherapy
Description: IV infusion
Study NCT02155218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Tailored Injection Rate
Description: Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves.
Study NCT02527434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 + tremelimumab combination therapy
Description: IV infusion
Study NCT01551914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Scissors (Ethicon)
Description: Haemostasis using Ultrasonic scissors
Study NCT01551914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)
Description: bipolar, monopolar or clip coagulation techniques
Study NCT03092778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.~The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn.
Study NCT01767597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELISA testing
Description: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
Study NCT01767597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELISA testing
Description: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
Study NCT01767597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid testing
Description: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
Study NCT01977430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and furosemide
Description: This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
Study NCT04346667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Regular dose
Description: Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Study NCT04346667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Loading Dose
Description: Hydroxychloroquine administered as a loading dose only
Study NCT04346667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Study NCT04346667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care plus placebo
Study NCT05591976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: 16-week, structured exercise training program including resistance and aerobic exercise
Study NCT03382626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
Study NCT03382626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted training
Description: The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
Study NCT03382626 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Computer-assisted training
Description: The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
Study NCT03382626 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
Study NCT01423435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP
Description: oral
Study NCT01416493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s.c. injections of bovine intestinal Alkaline Phosphatase
Description: daily subcutaneous treatment with two injections of 2000IU bIAP for three days
Study NCT04429568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smoked Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.
Study NCT04429568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaped Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
Study NCT00228904 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
Study NCT00228904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile IV insulin delivery (humalog, humulin, novolog)
Description: Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
Study NCT04429568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tobacco Cigarette
Description: Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
Study NCT03918551 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Febuxostat
Description: Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
Study NCT03918551 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adenuric
Description: Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
Study NCT04947228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trackPAD
Description: TrackPAD is a smartphone app to provide PAD-specific support for SET
Study NCT02008890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab 300mg
Description: Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
Study NCT01749176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS texting intervention
Study NCT04664023 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.
Description: 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
Study NCT02008890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg
Description: Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
Study NCT02008890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab 150mg
Description: secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
Study NCT02008890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Description: secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
Study NCT02008890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: secukinumab placebo s.c. (two PFS injections of placebo) self-administered
Study NCT02008890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: secukinumab placebo s.c. (two PFS injections of placebo) self-administered
Study NCT01610427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
Study NCT00499031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01368367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive exercise
Description: Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
Study NCT01368367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intensive exercise
Description: Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
Study NCT02250105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARI-3037MO
Description: Lipid lowering